Quesnel B, Preudhomme C, Oscier D, Lepelley P, Collyn-d'Hooghe M, Facon T, Zandecki M, Fenaux P
Inserm U124, Institut de Recherches sur le Cancer de Lille, France.
Br J Haematol. 1994 Oct;88(2):415-8. doi: 10.1111/j.1365-2141.1994.tb05044.x.
We looked for MDM2 gene amplification and over-expression by Southern and Northern blot analysis in 135 and 66 cases of haematological malignancies, including ALL, AML, CML in chronic phase, CLL, MDS, PLL, non-Hodgkin's lymphoma (NHL) and myeloma. No amplification of the gene was found. An over-expression of MDM2 RNA was seen in 9/66 (14%) patients tested, including 3/9 ALL, 3/24 AML, 2/4 myelomas, 1/1 PLL, but 0/2 CML, 0/2 NHL and 0/21 MDS. None of the patients over-expressing MDM2 had modifications of P53 gene transcript or p53 mutations. Most of the patients over-expressing MDM2 gene had poor prognostic features (including 'unfavourable' cytogenetic abnormalities), poor response to chemotherapy and short survival. Our findings suggest that over-expression of MDM2 is seen in a relatively small number of haematological malignancies, and is associated with poor prognosis.
我们通过Southern印迹和Northern印迹分析，在135例和66例血液系统恶性肿瘤患者中检测MDM2基因扩增及过表达情况，这些患者包括急性淋巴细胞白血病（ALL）、急性髓系白血病（AML）、慢性期慢性髓系白血病（CML）、慢性淋巴细胞白血病（CLL）、骨髓增生异常综合征（MDS）、多毛细胞白血病（PLL）、非霍奇金淋巴瘤（NHL）和骨髓瘤。未发现该基因扩增。在66例接受检测的患者中，有9例（14%）出现MDM2 RNA过表达，其中包括3例ALL、3例AML、2例骨髓瘤、1例PLL，但慢性粒细胞白血病（CML）2例、非霍奇金淋巴瘤（NHL）2例及骨髓增生异常综合征（MDS）21例均未出现过表达。MDM2过表达的患者中，均未出现P53基因转录本修饰或P53基因突变。大多数MDM2基因过表达的患者预后较差（包括“不良”细胞遗传学异常），对化疗反应不佳且生存期短。我们的研究结果表明，MDM2过表达在相对少数的血液系统恶性肿瘤中出现，且与预后不良相关。
